Prestige Biopharma Decides on 53.7 Billion KRW Capital Increase for Subsidiary
[Asia Economy Reporter Ji Yeon-jin] Prestige Biopharma announced on the 26th that its subsidiary, Prestige Biopharma Korea, has decided on a paid-in capital increase worth 53.7 billion KRW through a rights offering to shareholders. The new shares to be issued through this paid-in capital increase amount to 10,747,800 shares.
Hot Picks Today
"Buy on Black Monday"... Japan's Nomura Forecasts 590,000 for Samsung, 4 Million for SK hynix
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- "We're Now Earning 10 Million Won a Month"... Semiconductor Boom Drives Performance Bonuses at Major Electronic Component Firms
- 'Bond King' Gundlach: "Rate Cuts Impossible... CPI Could Rise to 4%"
- Experts Are Already Watching Closely..."Target Stock Price 970,000 Won" Now Only the Uptrend Remains [Weekend Money]
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
